Epigenomic perturbation of novel <i>EGFR</i> enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide

Abstract excerpt

<h4>ABSTRACT</h4> Glioblastoma (GB) is the most aggressive of all primary brain tumours. Patients typically rely on radiotherapy with concurrent temozolomide (TMZ) treatment and face a median survival of ∼14 months. Alterations in the Epidermal Growth Factor Receptor gene ( EGFR ) are common in GB tumours, but therapies targeting EGFR have not shown significant clinical efficacy. Here, we investigated the influe...

Topics

Open a Topic to create a Post that cites this publication.

• CRISPR-Associated Protein 9
• CRISPR-Cas Systems
• Endonucleases
• Gene Editing
• Gene Transfer Techniques
• Genetic Therapy
• Glioblastoma
• Glioma Diagnosis and Treatment

Identifiers and source

Literature Corpus work

93372925-c951-5274-9650-6803ccb09592

DOI

10.1101/2023.02.22.529507